Latest news on Laboratorytalk categorised by supplier
Oxford BioMedica
Address:
Medawar Centre
Robert Robinson Avenue
Oxford
OX4 4GA
UK
Telephone: (UK) +44 1865 783 000
http://www.oxfordbiomedica.co.uk
Our RSS feed for news from Oxford BioMedica
Request to receive our free email newsletter each week
Listing of all 89 news releases from Oxford BioMedica:
Oxford Biomedica buys RNA interference technology
Technical background article The rights granted are exclusive for RNAi gene silencing using lentiviral vector technology for human gene therapy applications, including Oxford BioMedica's proprietary LentiVector system
News from Oxford BioMedica ( 8 January 2008)
Agreement to commercialise Trovax for cancer
Oxford BioMedica and Sanofi-Aventis have entered into an exclusive global licensing agreement to develop and commercialise Trovax for the treatment and prevention of cancers
News from Oxford BioMedica (29 March 2007)
Oxford Biomedica to acquire Oxxon Therapeutics
Acquisition of privately held biotechnology company, based in Oxford, UK, adds melanoma cancer vaccine and extends immunotherapy platform
News from Oxford BioMedica (13 March 2007)
Avian transgenics: Interferon Alpha in eggs
Technical background article Oxford BioMedica, Viragen , and Roslin Institute, announce the successful expression of human interferon alpha-2a in the whites of eggs laid by transgenic hens using the Ova system
News from Oxford BioMedica (25 January 2007)
Avian transgenic results in scientific journal
Technical background article PNAS has published an article profiling the avian transgenic (Ova) system's ability to express two therapeutic proteins in the whites of eggs of transgenic hens
News from Oxford BioMedica (17 January 2007)
TroVax trial adopted by UK clinical trial network
Oxford BioMedica reports that the Phase III Trist trial of its novel cancer immunotherapy, TroVax, in patients with renal cancer, has been adopted by the UK National Cancer Research Network (NCRN)
News from Oxford BioMedica (11 January 2007)
Glaxosmithkline licences Lentivector technology
User application article Oxford BioMedica and Sigma-Aldrich have signed a joint licence agreement for LentiVector technology with GlaxoSmithKline (GSK), which provides GSK with access to the technology for research activities
News from Oxford BioMedica (25 December 2006)
Expanded licencing agreement for Lentivector
Oxford BioMedica has expanded an existing licence agreement for its LentiVector technology with a major multinational pharmaceutical company
News from Oxford BioMedica (20 December 2006)
EU orphan drug designation for Trovax
Oxford BioMedica's Trovax receives positive recommendation for orphan drug designation in renal cancer from EMEA
News from Oxford BioMedica (11 December 2006)
Encouraging data with Prosavin in Parkinson's
Preclinical efficacy results with gene-based product for Parkinson's disease, ProSavin, were presented at 14th Annual Congress of the European Society of Gene Therapy (ESGT) in Athens, November 2006
News from Oxford BioMedica (16 November 2006)
Encouraging results with Trovax in cancer
RCC trials are designed to evaluate the safety, immunogenicity and effectiveness of TroVax as a single agent and in combination with standard therapy of interleukin-2 (IL-2) or interferon-a (IFN)
News from Oxford BioMedica (16 November 2006)
Phase III trial of Trovax in renal cancer
Oxford BioMedica says the first patient has been treated in Trist, a multi-centre Phase III trial of cancer immunotherapy TroVax in patients with advanced or metastatic renal cell carcinoma (RCC)
News from Oxford BioMedica ( 8 November 2006)
Encouraging immunological data from Trovax trials
Oxford BioMedica has presented further 'encouraging' data from six Phase II trials of TroVax, at the 14th International Cancer Immunotherapy Meeting, 4-6 October 2006 in New York City
News from Oxford BioMedica ( 9 October 2006)
Gene therapy products to treatment eye diseases
Oxford Biomedica expands its ocular programme through collaboration and investment led by the Foundation Fighting Blindness
News from Oxford BioMedica ( 3 October 2006)
Swog group starts trial of Trovax in breast cancer
Regulatory clearance for start of patient recruitment in 120-patient Phase II trial of TroVax in patients with late-stage breast cancer
News from Oxford BioMedica ( 6 September 2006)
Clinician presents on Trovax at cancer conference
Principal Investigator for TroVax Phase II trials to present at Cancer Immunotherapuetics and Vaccines meeting in Cambridge, Massachusetts, on 22-23 August 2006
News from Oxford BioMedica (22 August 2006)
'Breakthrough' in gene therapy technology
Oxford BioMedica and researchers at Imperial College of Science and Technology, London announced in June 2002 that they had achieved very efficient gene transfer to mouse embryos in utero
News from Oxford BioMedica (11 August 2006)
Successful preclinical results for anaemia product
Oxford BioMedica announced in June 2002 that it had added a new product Repoxygen, to treat anaemia, to its development portfolio.
News from Oxford BioMedica (11 August 2006)
Research with Institute of Ophthalmology
Age-related macular degeneration (AMD) and diabetic retinopathy (DR) affect approximately 30 million people in the developed world and the market potential is in excess of $1.0 billion
News from Oxford BioMedica (11 August 2006)
Gene therapy for Parkinson's: positive results
Oxford BioMedica presented preclinical data for its Parkinson's disease product, ProSavin at the 31st Annual Meeting of the American Society of Neurosciences in November 2001
News from Oxford BioMedica (11 August 2006)
Successful interim phase I/II Trovax results
Termination of collaboration with Modex
GTAC approval for development of Metxia programme
Fundamental patent for Lentiviral gene therapy
Exclusive access to antibody technology
Gene Therapy Patent in the USA
$0.5 million grant for Motor Neuron Disease
Collaboration attracts first development partner
Collaborative programme in tumour immunotherapy
Positive results for therapeutic cancer vaccine
Joining the fight against Lou Gehrig's Disease
Grant support for cancer immunotherapy programmes
Collaborative programme on wound healing
Research and development deal with Intervet Pharma
Funding from the Foundation Fighting Blindness
MoNuDin in the treatment of motor neuron disease
Metxia enters clinical trials in pancreatic cancer
Oxford Biomedica acquires Chiron patents
Scientists pioneer motor neuron disease treatment
FDA approval for trial of Trovax in renal cancer
Grant from UK gene therapy research programme
LentiVector licensing agreement with Merck
Phase II trial with TroVax in colorectal cancer
Cytochrome P450 enzymes in cancer gene therapy
Positive results with Trovax in colorectal cancer
Lentivector for avian transgenics biomanufacturing
Lentivector success in avian transgenics
Oxford Biomedica - Innurex programme
Lentivector licensing agreement signed
Lentivector licensing agreement with Biogen Idec
Potential for treatment of spinal muscular atrophy
Ex vivo gene technology licensed to Molmed
Extended collaboration on novel cancer targets
Notice of allowance for US Lentivector patent
Lentivector is the 'system of choice' for RNAI
Progress in avian transgenics biomanufacturing
Grant for Monudin from motor neurone association
Key lentivector patents in China
Lentivector licensing agreement with Pfizer
Report of avian transgenic milestone
European patent for Trovax covering 5T4 tumour
Antibody therapy for treatment of solid tumours
Phase II results with Metxia in pancreatic cancer
Encouraging Phase II results in renal carcinoma
Successful Phase II trial in pancreatic cancer
Patent allowance extends Trovax protection in USA
Phase II trial with Trovax in renal cell carcinoma
Innurex nerve regeneration programme highlighted
Lentivector licensing agreement signed
Alliance for commercialisation of lentivector
Agreement with FDA on Trovax in renal cancer
Encouraging preclinical data in retinopathy
Licensing gene delivery technology to Virxsys
Allowance for key US patent covering Parkinson's
Phase II trial of Trovax in prostate cancer
Phase II results with Trovax are 'encouraging'
Oxford Biomedica announces board appointment
Avian transgenic breakthrough reported
Agreement with EntreMed on RetinoStat programme
Further TroVax phase ii trial in colorectal cancer
Further patent for LentiViral gene therapy
Positive results from MetXia breast cancer trial
Manufacturing process for Parkinson's drug
TroVax passes key regulatory hurdle in the USA
Preclinical results from the RetinoStat
Genetic vector technology licenced
Colorectal cancer drug gets Phase II go-ahead
Wyeth exercises option on anti-tumour antibody
Ethical approval for TroVax trial
